Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endologix investigates new Powerlink graft in large diameter aneurysm necks:

This article was originally published in Clinica

Executive Summary

Seeking to broaden the market for its Powerlink stent graft for treating abdominal aortic aneurysm (AAA), Endologix has begun a US clinical trial to test a modified version the device designed to treat aneurysms with larger neck diameters. If approved, the new device could become the first endoluminal stent graft (ELG) for use in aneurysms with neck diameters up to 32mm, according to the Irvine, California firm, which has already received FDA approval to sell the original form of the product. "The Powerlink 34mm system has the ability to expand the universe of AAA patients suitable for minimally invasive ELGs as approximately 5-10% of those evaluated are excluded due to a large aortic neck diameter," said Paul McCormick, Endologix' president and CEO.

You may also be interested in...

Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.

First-Of-Its-Kind Prostate Cancer Imaging Agent Approved By FDA

Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts